Drug Profile


Alternative Names: LBM 642

Latest Information Update: 03 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Carboxylic acids; Indoles; Oxazoles; Sulfonamides
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Lipid metabolism disorders

Most Recent Events

  • 31 Dec 2007 Discontinued - Phase-II for Lipid metabolism disorders in Switzerland (unspecified route)
  • 22 May 2007 LBM 642 is still in active development
  • 03 Feb 2005 Phase-I clinical trials in Metabolic syndrome in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top